生物活性：Taurodeoxycholate-d6 sodium salt is a bile salt-related anionic detergent. Taurodeoxycholate-d6 sodium salt is formed in the liver by conjugation of deoxycholate with Taurine (HY-B0351). Taurodeoxycholate-d6 sodium salt is used for isolation of membrane proteins including inner mitochondrial membrane proteins. Taurodeoxycholate-d6 (TDCA) exhibits anti-inflammatory and neuroprotective effects[1][2][3][9][10].
体外研究(In Vitro)：Taurodeoxycholate-d6 sodium salt (Taurodeoxycholic acid form) 通过荧光素酶检测，对 CHO 细胞中表达的人 TGR5 具有激动活性，EC50 为 0.79 μM[4]。
Taurodeoxycholate-d6 sodium salt (Taurodeoxycholic acid form, 16 h) 对在 HEK293 细胞中表达的野生型和 Y89A 突变型人 TGR5 具有激动剂活性，其 EC50 分别为 0.68 和 8.9 μM (以细胞内 cAMP 水平的升高来评估)[5]。
Taurodeoxycholate-d6 sodium salt (Taurodeoxycholic acid form, 50-100 μM，4 h) 增加原代人肝细胞中寡核体 DNA 切割和细胞核凋亡[6]。
Taurodeoxycholate-d6 sodium salt (Taurodeoxycholic acid form, 400 μM，18-24 h) 在人肝来源的 Huh7 细胞中增加 DNA 碎片和 PARP 切割，诱导凋亡[7]。
Taurodeoxycholate-d6 (0.05-1.00 mM，1-6 天) sodium salt 刺激肠上皮细胞增殖[8]。
Taurodeoxycholate-d6 (0.05-1.00 mM，24 h) sodium salt 诱导细胞周期的S期浓度显著增加和 G1 期浓度显著降低，增加c-myc IEC-6细胞蛋白和 mRNA 的表达[8]。
Taurodeoxycholate-d6 (25-400 ng/mL，稀释四倍，3 h) sodium salt 通过激活 cAMP-PKA 轴，抑制脂多糖激活的骨髓源性巨噬细胞 (BMDMs) 中 NF-κB 的活化[9]。
试剂家 has not independently confirmed the accuracy of these methods. They are for reference only.
Taurodeoxycholate-d6 sodium salt 相关抗体:
BNSP Antibody
FACL4 Antibody
BrdU Antibody (YA578)
ERK1/2 Antibody
NF-KB p65 Antibody
Phospho-NF-KB p65 (Ser536) Antibody
E-Cadherin Antibody (YA470)
Fatty Acid Synthase Antibody (YA766)
DYKDDDDK Tag (FLAG) Antibody
GAPDH Antibody
GFP Antibody
p53 Antibody (YA250)
RUNX2 Antibody
Phospho-NF-κB p65 (Ser529) Antibody
Ferritin Heavy Chain Antibody
Glucose 6 Phosphate Dehydrogenase Antibody
COX2 Antibody
Ctip2 Antibody
Cyclin D1 Antibody (YA485)
Cytochrome C Antibody
METTL3 Antibody
NF-KB p65 Antibody (YA267)
c-Myc Antibody
Cyclin E1 Antibody
TSG101 Antibody
AIF Antibody (YA636)
ALIX Antibody
Alkaline Phosphatase Antibody
Calnexin Antibody (YA573)
CNPase Antibody
Cell Proliferation Assay[8]
Cell Line:
IEC-6 and caco-2 cells
Concentration:
0, 0.05, 0.50, and 1.00 mM
Incubation Time:
1, 2, 4 and 6 days
Result:
Significantly stimulated intestinal epithelial cell proliferation in a dose-dependent manner.
Cell Cycle Analysis[8]
Cell Line:
IEC-6 cells
Concentration:
0, 0.05, 0.50, and 1.00 mM
Incubation Time:
24 h
Result:
Significantly increased cells in S phase and decreased cells in G1-phase.
Western Blot Analysis[8]
Cell Line:
IEC-6 cells
Concentration:
0.5 mM
Incubation Time:
1 and 6 days
Result:
Significantly increased c-myc protein expression.
体内研究(In Vivo)
Taurodeoxycholate-d6 (1.25-5 mg/kg，口服，6 天) sodium salt 可改善右旋糖酐硫酸钠 (DSS) 诱导的小鼠结肠炎[9]。
Taurodeoxycholate-d6 sodium salt (Taurodeoxycholic acid form，50 mg/kg，腹腔注射，每天 1 次，共 34 天) 预防亨廷顿舞蹈病 (HD) 大鼠模型的神经病理和相关的行为缺陷[10]。
Taurodeoxycholate-d6 sodium salt (Taurodeoxycholic acid form，500 mg/kg，皮下注射，每 3 天 1 次，共 7 周) 导致 R6/2 转基因 HD 小鼠纹状体神经病理的显著降低[11]。
Taurodeoxycholate-d6 (0.5 mg/kg，静脉注射，一次) sodium salt 对患有脓毒症的 C57BL/6N 小鼠提供保护，但不能保护患有脓毒症的 TGR5 KO 小鼠[12]。
试剂家 has not independently confirmed the accuracy of these methods. They are for reference only.
Animal Model:
A mouse colitis model (fed with 3% (w/v) DSS in drinking water for the first seven days and then switched to normal drinking water for an additional two days)[9]
Dosage:
1.25, 2.5, and 5 mg/kg
Administration:
Oral gavage (p.o.), from day 3 to day 8, once a day
Result:
Prevented loss of body weight, shortening of the colon, production of pro-inflammatory cytokines, infiltration of pro-inflammatory cells, and mucosal ulceration in the colon.
Animal Model:
Huntington's disease model in mouse[10]
Dosage:
50 mg/kg
Administration:
Intraperitoneal injection; once daliy for 34 d, injected 3-NP at 6 hr after Taurodeoxycholic acid treatment
Result:
Reduced striatal atrophy, decreased striatal apoptosis, as well as fewer and smaller size ubiquitinated neuronal intranuclear huntingtin inclusions.
Significantly improved locomotor and sensorimotor deficits.
Animal Model:
C57BL/6N mice, Lipopolysaccharides (HY-D1056) injection model of sepsis[12]
Dosage:
0.5 mg/kg
Administration:
Intravenous injection, 30 min or 24 h after LPS injection
Result:
Improved the survival rate of mice with sepsis.
Decreased liver and kidney damage in septic mice.
Ameliorated systemic inflammation and normalized blood pressure in septic mice.
分子量：528.73
Formula：C26H39D6NNaO6S
CAS 号：2687960-92-3
非标记 CAS：1180-95-6
性状：固体
颜色：White to off-white
中文名称：牛磺脱氧胆酸钠-d6
运输条件：Room temperature in continental US; may vary elsewhere.
储存方式：4°C, sealed storage, away from moisture
*In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
纯度 & 产品资料
纯度： 99.4%
参考文献
[1]. Villavicencio-Queijeiro A, et al. The fully-active and structurally-stable form of the mitochondrial ATP synthase of Polytomella sp. is dimeric. J Bioenerg Biomembr. 2009 Feb;41(1):1-13.
 [Content Brief]
[2]. Kispal G, et al. Isolation and characterization of 3-hydroxyacyl coenzyme A dehydrogenase-binding protein from pig heart inner mitochondrial membrane. J Biol Chem. 1986 Oct 25;261(30):14209-13.
 [Content Brief]
[3]. Choi HJ, et al. Evaluation of acute and subacute toxicity of sodium Taurodeoxycholate in rats. Drug Chem Toxicol. 2021 May;44(3):268-276.
 [Content Brief]
[4]. Sato H, et al. Novel potent and selective bile acid derivatives as TGR5 agonists: biological screening, structure-activity relationships, and molecular modeling studies. J Med Chem. 2008 Mar 27;51(6):1831-41.
 [Content Brief]
[5]. Gertzen CG, et al. Mutational mapping of the transmembrane binding site of the G-protein coupled receptor TGR5 and binding mode prediction of TGR5 agonists. Eur J Med Chem. 2015 Nov 2;104:57-72.
 [Content Brief]
[6]. Benz C, et al. Effect of tauroursodeoxycholic acid on bile acid-induced apoptosis in primary human hepatocytes. Eur J Clin Invest. 2000 Mar;30(3):203-9.
 [Content Brief]
[7]. Xie Q, et al. Effect of tauroursodeoxycholic acid on endoplasmic reticulum stress-induced caspase-12 activation. Hepatology. 2002 Sep;36(3):592-601.
 [Content Brief]
[8]. Yamaguchi J, et al. Taurodeoxycholate increases intestinal epithelial cell proliferation through c-myc expression. Surgery. 2004 Feb;135(2):215-21.
 [Content Brief]
[9]. Zou Y, et al. Taurodeoxycholate ameliorates DSS-induced colitis in mice. Int Immunopharmacol. 2023 Sep;122:110628.
 [Content Brief]
[10]. Keene CD, et al. A bile acid protects against motor and cognitive deficits and reduces striatal degeneration in the 3-nitropropionic acid model of Huntington's disease. Exp Neurol. 2001 Oct;171(2):351-60.
 [Content Brief]
[11]. Keene CD, et al. Tauroursodeoxycholic acid, a bile acid, is neuroprotective in a transgenic animal model of Huntington's disease. Proc Natl Acad Sci U S A. 2002 Aug 6;99(16):10671-6.
 [Content Brief]
[12]. Chang S, et al. Taurodeoxycholate Increases the Number of Myeloid-Derived Suppressor Cells That Ameliorate Sepsis in Mice. Front Immunol. 2018 Sep 18;9:1984.
 [Content Brief]